Indira Gandhi Institute of Medical Sciences, an Institute under State Legislature Act, was established on 19 November 1983 as an autonomous organisation on the pattern of All India Institute of Medical Sciences, New Delhi. The estimated budget was 110 crore rupees which was later revised to 133 crores.

During the past decade, Regional Cancer Centre Indira Gandhi Institute of Medical Sciences conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Regional Cancer Centre Indira Gandhi Institute of Medical Sciences" #1 sponsor was "Helsinn Therapeutics (U.S.), Inc" with 1 trials, followed by "Imugene Limited" with 1 trials sponsored, "Mylan Pharmaceuticals Inc" with 1 trials sponsored, "Viela Bio (acquired by Horizon Therapeutics)" with 1 trials sponsored and "Zymeworks Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Regional Cancer Centre Indira Gandhi Institute of Medical Sciences" #1 collaborator was "BeiGene, Ltd." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Regional Cancer Centre Indira Gandhi Institute of Medical Sciences" are "Adenocarcinoma" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Esophageal Adenocarcinoma" (1 trials), "Gastric Neoplasms" (1 trials) and "Gastroesophageal Adenocarcinoma" (1 trials). Many other conditions were trialed in "Regional Cancer Centre Indira Gandhi Institute of Medical Sciences" in a lesser frequency.

Most popular intervention types in "Regional Cancer Centre Indira Gandhi Institute of Medical Sciences" are "Drug" (4 trials), "Biological" (2 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "5-Fluorouracil" (1 trials), "Bevacizumab as Avastin" (1 trials), "Bevacizumab as MYL-1402O" (1 trials), "Capecitabine" (1 trials) and "Cisplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Regional Cancer Centre Indira Gandhi Institute of Medical Sciences" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Regional Cancer Centre Indira Gandhi Institute of Medical Sciences". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Regional Cancer Centre Indira Gandhi Institute of Medical Sciences, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Regional Cancer Centre Indira Gandhi Institute of Medical Sciences, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".